Proton pump inhibitors are associated with a reduced likelihood for sexually transmitted diseases in women in the emergency department

Proton pump inhibitors (PPIs) have been shown in cell culture to kill (TV) at lower half maximal inhibitory concentration values than metronidazole (Flagyl), the most common medication used to treat the infection. However, there have been no previous clinical investigations to determine if PPIs are...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Indian Journal of Sexually Transmitted Diseases and AIDS 2017-01, Vol.38 (1), p.60-64
Hauptverfasser: Sheele, Johnathan Michael, Morris, Nathan, Byars, Donald, Counselman, Frank
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Proton pump inhibitors (PPIs) have been shown in cell culture to kill (TV) at lower half maximal inhibitory concentration values than metronidazole (Flagyl), the most common medication used to treat the infection. However, there have been no previous clinical investigations to determine if PPIs are associated with reduced risk for TV. We examined the records of female patients who received testing in the emergency department for TV, (GC), and (CT) between 2010 and 2014 at two academic medical centers to determine if PPI and histamine type 2 receptor antagonist (H2RA) drugs were associated with TV and GC/CT infections. We found that H2RAs were associated with an increased likelihood for TV (odds ratio [OR]: 2.0, < 0.0001) and GC and/or CT infections (OR: 1.49, < 0.0001). PPIs were associated with a reduced likelihood for TV (OR: 0.75, < 0.0001) and GC and/or CT infections (OR: 0.57, < 0.0001). In patients infected with GC and/or CT, the likelihood of coinfection with TV was reduced in those taking a PPI (OR: 0.64, = 0.054) and increased in those taking an H2RA (OR: 1.62, = 0.003). PPIs are associated with a reduced risk for TV and GC/CT infection.
ISSN:2589-0557
1998-3816
2589-0565
DOI:10.4103/0253-7184.203438